Three investigators from the University of Hong Kong (HKU), one from the Chinese University of Hong Kong (CUHK) and one from the Hong Kong University of Science and Technology (HKUST) received the prestigious Croucher Senior Medical Research Fellowship and Croucher Innovation Awards.
The CUHK Medical Centre, a nonprofit, self-financed teaching hospital of the Chinese University of Hong Kong (CUHK), is expected to commence operation in the second quarter of 2020.
Pembrolizumab is cost-effective in the first-line treatment of advanced melanoma in Hong Kong compared with ipilimumab and standard chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress held recently in Singapore.
Findings from a phase III trial show that the anti-CD30 antibody-drug conjugate, brentuximab vedotin (BV), is superior to methotrexate or bexarotene in the efficacy endpoint of overall response rate (ORR) lasting ≥4 months in the treatment of cutaneous T cell lymphoma (CTCL).
Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, may help reduce the symptoms of atopic dermatitis, according to the results of two randomized, double-blind, placebo-controlled, phase III trials.
Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.